Episode 125: AML Series, Pt 11 - Treatment of patients unfit for intensive therapy
Dec 18, 2024
auto_awesome
Explore innovative treatment strategies for elderly patients with acute myeloid leukemia who can't handle intensive therapy. Learn about assessing fitness for treatment and the significance of genetic mutations. Discover how modern therapies like azacitidine and venetoclax are reshaping care for frail patients. Key clinical trials, including Viali-A and LACEWING, reveal improved outcomes. The episode delivers valuable insights into navigating the complexities of AML management in older, less fit patients.
Assessing patient fitness for intensive AML therapy relies on comprehensive evaluations, highlighting the challenges of current assessment tools and their limitations.
Recent advancements in AML treatment, including hypomethylating agents and venetoclax, offer improved survival rates for older patients unfit for intensive chemotherapy.
Deep dives
Understanding Patient Fitness for Treatment
Defining which patients are fit for intensive chemotherapy is crucial in managing elderly patients with acute myeloid leukemia (AML). Fitness assessments often rely on clinical judgment and holistic evaluations, encompassing various tools such as ECOG and Karnofsky performance status. However, these measures can be misleading due to their broad nature and lack of specificity regarding comorbid conditions. The challenge lies in determining which patients may be better served by supportive care rather than intensive therapies, emphasizing the need for further research into geriatric assessments and treatments tailored for frail patients.
The Evolution of AML Treatment for Older Patients
For older patients diagnosed with AML, treatment options have evolved significantly over the decades. Low-dose cytarabine was once considered the standard of care, but its modest efficacy led to the development of hypomethylating agents like azacitidine and decitabine. These agents demonstrated improved survival rates in older patients who were not fit for intensive therapy, helping reshape the treatment landscape. Recent clinical trials have established combinations involving these agents with other medications, such as venetoclax, significantly enhancing the response rates and overall survival for this patient demographic.
Innovative Therapies and Risk Stratification
Recent advancements in the treatment of AML have led to new strategies involving molecular data for risk stratification among older patients. With the approval of venetoclax and its combination with hypomethylating agents, outcomes for patients with specific genetic mutations, such as IDH1, have shown substantial improvement in response rates. The introduction of refined risk categories based on molecular profiles has also suggested tailored treatment regimens for better patient management. These developments are essential, as they allow for a more precise approach to therapy, catering to the individual needs of patients based on their genetic characteristics.
Future Directions in AML Treatment Research
The landscape of AML treatment is evolving with ongoing research into novel regimens and potential combinations that go beyond current standards. Promising studies are investigating the efficacy of triplet therapies utilizing hypomethylating agents, venetoclax, and various targeted inhibitors, which could enhance treatment outcomes. There is an emphasis on the importance of randomized phase three trials to validate the effectiveness of these combinations, as anecdotal successes must transition into structured research. Future studies aim to balance effective treatment with cost, ensuring the best possible outcomes for patients while considering the financial implications of new therapies.
In today’s episode, we discuss how to approach AML treatment for patients who are unfit for intensive therapy.
Episode contents:
- How do we assess fitness for intensive AML?
- What are options for patients who are unfit for intensive chemotherapy for AML?
- What are important genetic mutations are important to check for?
- What are the key trials that inform our management in this space?
- How do we dose venetoclax?
- How do we sequence the available agents?
****Get paid to participate in market research surveys: https://affiliatepanel.members-only.online/FOC_24?utm_campaign=FOC&utm_source=email&utm_medium=email
** Want to review the show notes for this episode and others? Check out our website: https://www.thefellowoncall.com/our-episodes
Love what you hear? Tell a friend and leave a review on our podcast streaming platforms!
Twitter: @TheFellowOnCall
Instagram: @TheFellowOnCall
Listen in on: Apple Podcast, Spotify, and Google Podcast
Get the Snipd podcast app
Unlock the knowledge in podcasts with the podcast player of the future.
AI-powered podcast player
Listen to all your favourite podcasts with AI-powered features
Discover highlights
Listen to the best highlights from the podcasts you love and dive into the full episode
Save any moment
Hear something you like? Tap your headphones to save it with AI-generated key takeaways
Share & Export
Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more
AI-powered podcast player
Listen to all your favourite podcasts with AI-powered features
Discover highlights
Listen to the best highlights from the podcasts you love and dive into the full episode